

Learn about pharmaceutical company compliance requirements in Turkey in 2026. Discover licensing obligations, GMP compliance, pharmacovigilance requirements, GDP standards, pharmaceutical advertising rules, regulatory inspections, product safety obligations, and legal requirements for pharmaceutical companies.
Turkey has one of the most highly regulated pharmaceutical sectors in the region. Pharmaceutical companies operating in Turkey must comply with a comprehensive legal framework governing drug licensing, manufacturing, importation, distribution, marketing, pharmacovigilance, product safety, clinical trials, data protection, and healthcare compliance. The Turkish pharmaceutical market continues to attract domestic and foreign investors due to its large population, advanced healthcare infrastructure, growing healthcare expenditure, and strategic location connecting Europe, Asia, and the Middle East.
However, the pharmaceutical sector is subject to intensive oversight by regulatory authorities. Pharmaceutical companies are expected to maintain continuous compliance throughout the entire product lifecycle, from licensing and manufacturing to distribution, post-market surveillance, and product recalls. Compliance failures may result in administrative fines, suspension of activities, product withdrawals, license cancellations, reputational damage, and significant legal liability.
This 2026 Legal Guide explains the most important compliance requirements applicable to pharmaceutical companies operating in Turkey.
The primary regulatory authority overseeing pharmaceutical activities in Turkey is the Turkish Medicines and Medical Devices Agency (TITCK), operating under the Ministry of Health.
TITCK is responsible for:
The agency supervises the entire pharmaceutical supply chain and possesses extensive enforcement powers regarding compliance violations.
Foreign and domestic investors may establish pharmaceutical companies in Turkey through standard corporate structures.
Common structures include:
Although company formation follows general corporate procedures, pharmaceutical activities frequently require additional regulatory approvals before operations may commence. Corporate registration alone does not authorize pharmaceutical activities.
One of the most important compliance requirements concerns pharmaceutical product licensing.
Before a medicinal product may be placed on the Turkish market, authorization from TITCK is generally required.
The licensing process typically evaluates:
Licensing should not be viewed as a one-time approval. Compliance obligations continue after market authorization and remain applicable throughout the product’s commercial lifecycle.
Pharmaceutical manufacturers must comply with Good Manufacturing Practice (GMP) requirements.
GMP systems generally cover:
Manufacturing facilities are subject to inspections and ongoing regulatory monitoring.
Failure to maintain GMP compliance may lead to manufacturing restrictions, suspension of production activities, or product-related regulatory actions.
Distribution activities are subject to Good Distribution Practice (GDP) standards.
GDP requirements generally focus on:
The Turkish regulatory authority has issued detailed guidance regarding GDP inspections and compliance expectations for pharmaceutical distributors. GDP inspections are designed to ensure proper storage, transportation, and distribution of medicinal products.
Pharmacovigilance is one of the most important post-market obligations facing pharmaceutical companies.
Pharmacovigilance systems generally involve:
Pharmaceutical companies are expected to maintain systems capable of identifying, evaluating, and reporting product safety concerns throughout the life of a medicinal product. Post-licensing pharmacovigilance remains a central component of regulatory compliance.
Pharmaceutical companies involved in international trade must comply with additional regulatory requirements.
These may include:
International pharmaceutical transactions are subject to both healthcare regulations and customs legislation.
Proper regulatory planning is essential before engaging in cross-border pharmaceutical activities.
Product safety obligations continue throughout the product lifecycle.
Under Turkish legislation, manufacturers and importers may face liability for unsafe products that cause harm to individuals or property.
Compliance obligations typically include:
Regulatory approval does not automatically eliminate potential liability arising from defective pharmaceutical products.
Advertising and promotional activities are strictly regulated.
Pharmaceutical companies must ensure that:
Off-label promotion and unauthorized advertising activities may trigger regulatory investigations and administrative sanctions.
Companies conducting clinical research must comply with strict regulatory requirements.
Clinical trial obligations may include:
Unauthorized clinical trials may result in significant legal consequences.
Clinical trial compliance remains a major area of regulatory scrutiny.
Pharmaceutical companies frequently process sensitive health-related information.
Compliance obligations generally include:
Healthcare-related data is often subject to enhanced protection requirements.
Comprehensive privacy compliance programs are essential for pharmaceutical businesses.
Pharmaceutical companies should expect periodic inspections and audits.
Regulatory reviews may focus on:
Authorities possess broad inspection powers and may impose sanctions for identified deficiencies.
Pharmaceutical companies must maintain effective recall procedures.
Recall systems should enable businesses to:
Regulators expect companies to implement robust traceability and recall mechanisms throughout the supply chain.
The most common compliance challenges include:
Most risks can be significantly reduced through proactive compliance programs and internal audits.
The pharmaceutical industry operates within one of the most complex regulatory environments in Turkey.
Professional legal support can assist with:
Early legal guidance can significantly reduce regulatory risks and protect long-term business operations.
Yes. Foreign investors may establish pharmaceutical companies through Turkish corporate structures, subject to applicable pharmaceutical regulations.
The Turkish Medicines and Medical Devices Agency (TITCK) is the primary regulatory authority overseeing pharmaceutical activities.
Yes. Medicinal products generally require regulatory authorization before being placed on the market.
Good Manufacturing Practice (GMP) regulates pharmaceutical manufacturing quality systems and production standards.
Good Distribution Practice (GDP) governs pharmaceutical storage, transportation, and distribution activities.
Pharmacovigilance involves monitoring, evaluating, and reporting medicine safety information after products enter the market.
No. Pharmaceutical advertising and promotional activities are heavily regulated.
Yes. Regulatory authorities conduct inspections regarding manufacturing, distribution, quality systems, and compliance programs.
Licensing violations, GMP deficiencies, pharmacovigilance failures, GDP non-compliance, advertising violations, and data protection breaches.
Legal guidance helps companies maintain compliance, reduce regulatory risks, respond to inspections, and protect long-term business interests.
The pharmaceutical industry presents significant opportunities for investors, manufacturers, distributors, healthcare companies, and international life sciences businesses. However, successful participation in the pharmaceutical sector requires careful regulatory planning, ongoing compliance management, and effective risk mitigation strategies.
Whether you are establishing a pharmaceutical company, applying for product licenses, implementing GMP or GDP systems, launching distribution operations, conducting clinical research, managing pharmacovigilance obligations, or expanding pharmaceutical activities into Turkey, professional legal support can help protect your investment and ensure compliance with evolving regulatory requirements.
Phone: +90 312 434 22 22
Mobile Phone: +90 532 769 22 22
E-mail: info@firatfesihkaya.av.tr
Address: Mevlana Boulevard No:221, Yildirim Tower No:148, 06520 Balgat, Cankaya, Ankara, Turkey
Our law firm provides comprehensive legal services for pharmaceutical companies, healthcare investors, manufacturers, distributors, medical device companies, biotechnology businesses, healthcare technology providers, and multinational life sciences organizations operating in Turkey.